ceftazidima normon (ceftazidime) stungulyfsstofn og leysir, lausn 1 g
laboratorios normon s.a. - ceftazidimum inn - stungulyfsstofn og leysir, lausn - 1 g
ceftazidima normon (ceftazidime) innrennslisstofn, lausn 2 g
laboratorios normon s.a. - ceftazidimum inn - innrennslisstofn, lausn - 2 g
ceftazidim fresenius kabi stungulyfs-/innrennslisstofn, lausn 2000 mg
fresenius kabi ab - ceftazidimum pentahýdrat - stungulyfs-/innrennslisstofn, lausn - 2000 mg
ceftazidim fresenius kabi stungulyfsstofn, lausn 1000 mg
fresenius kabi ab - ceftazidimum pentahýdrat - stungulyfsstofn, lausn - 1000 mg
fortum stungulyfs-/innrennslisstofn, lausn 2 g
sandoz a/s - ceftazidimum inn - stungulyfs-/innrennslisstofn, lausn - 2 g
fortum stungulyfsstofn, lausn 1 g
sandoz a/s - ceftazidimum inn - stungulyfsstofn, lausn - 1 g
zavicefta
pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - sýklalyf fyrir almenn nota, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.
cinveron stungulyf, lausn 2 mg/ml
williams & halls ehf - ondansetronum hýdróklóríð - stungulyf, lausn - 2 mg/ml
fetcroja
shionogi b.v. - cefiderocol súlfat tosilate - gramm-neikvæð bakteríusýkingum - sýklalyf fyrir almenn nota, - fetcroja er ætlað fyrir meðferð sýkingum vegna úti gramm-neikvæð lífvera í fullorðnir með takmarkaða meðferð valkosti (sjá kafla 4. 2, 4. 4 og 5. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.
xydalba
abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - sýklalyf fyrir almenn nota, - meðferð við bráðum húð og sýkingar í húð (absssi) hjá fullorðnum.